Citadel Advisors
CRDF icon

Citadel Advisors’s Cardiff Oncology CRDF Stock Holding History

Citadel Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$240K Sell
184,400
-44,600
-19% -$70.8K ﹤0.01% 11639
2026
Q1 		$371K Sell
229,000
-43,800
-16% -$89.9K ﹤0.01% 9981
2025
Q4 		$767K Buy
272,800
+44,900
+20% +$104K ﹤0.01% 8011
2025
Q3 		$469K Buy
227,900
+142,300
+166% +$393K ﹤0.01% 9284
2025
Q2 		$270K Buy
85,600
+44,200
+107% +$135K ﹤0.01% 10047
2025
Q1 		$130K Sell
41,400
-86,500
-68% -$342K ﹤0.01% 11086
2024
Q4 		$555K Buy
127,900
+122,000
+2,068% +$381K ﹤0.01% 8328
2024
Q3 		$15.8K Sell
5,900
-18,000
-75% -$42.5K ﹤0.01% 12954
2024
Q2 		$53.1K Sell
23,900
-2,600
-10% -$9.8K ﹤0.01% 11690
2024
Q1 		$142K Buy
26,500
+19,000
+253% +$50.5K ﹤0.01% 10854
2023
Q4 		$11.1K Sell
7,500
-12,800
-63% -$15.5K ﹤0.01% 13058
2023
Q3 		$28.2K Buy
20,300
+10,200
+101% +$17.2K ﹤0.01% 12332
2023
Q2 		$14.8K Buy
10,100
+6,400
+173% +$10.3K ﹤0.01% 12983
2023
Q1 		$6.11K Buy
3,700
+1,200
+48% +$2.06K ﹤0.01% 13829
2022
Q4 		$3.5K Sell
2,500
-53,300
-96% -$76.3K ﹤0.01% 14203
2022
Q3 		$86K Buy
+55,800
New +$134K ﹤0.01% 11218
2022
Q1 		– Sell
-41,400
Closed -$249K – 13716
2021
Q4 		$249K Buy
41,400
+8,900
+27% +$53K ﹤0.01% 11365
2021
Q3 		$216K Sell
32,500
-12,900
-28% -$81K ﹤0.01% 11824
2021
Q2 		$302K Sell
45,400
-78,900
-63% -$669K ﹤0.01% 11254
2021
Q1 		$1.15M Buy
124,300
+23,700
+24% +$288K ﹤0.01% 7753
2020
Q4 		$1.81M Buy
100,600
+28,100
+39% +$494K ﹤0.01% 5536
2020
Q3 		$1.03M Buy
+72,500
New +$479K ﹤0.01% 5981
2016
Q4 		– Sell
-178
Closed -$57K – 7308
2016
Q3 		$57K Buy
+178
New +$64.9K ﹤0.01% 6828

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors's CRDF Position: Q2 2026 in Review

Citadel Advisors sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 125,566 shares — an estimated $199K sold.

Citadel Advisors first reported a position in CRDF in Q1 2014 and held it in 27 quarters. The position peaked at $15.6M in Q4 2020. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • Citadel Advisors reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 125,566 Cardiff Oncology shares in Q2 2026, an estimated $199K.
  • Citadel Advisors first reported a position in Cardiff Oncology in Q1 2014 and held it in 27 quarters.
  • Citadel Advisors's Cardiff Oncology position peaked at $15.6M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.